

Original Research Article

Serum leptin concentration in impaired glucose tolerance and recent onset type ii diabetes mellitus, relationship with anthropometry and lipid profile**Koppukonda Ravi Babu^{1*}, B.Aparna Varma², Bonagiri Shanthi³**¹*Assistant Professor, Department of Biochemistry, Mallareddy Institute of Medical Sciences, Hyderabad, Telangana, India*²*Professor & HOD, Department of Biochemistry, AIIMS Bibinagar, Hyderabad, Telangana, India*³*Professor & HOD, Transfusion Medicine And Immuno Haematology, NIMS, Hyderabad, Telangana, India*

Received: 30-11-2021 / Revised: 22-12-2021 / Accepted: 03-01-2022

Abstract

Diabetes as well as pre-diabetes or impaired glucose tolerance increases the risk of cardiovascular disease by 2–3 times and increases by as much as 50% the risks of non-cardiovascular mortality associated with this condition. This study aim is to measure serum leptin levels in correlation with anthropometry and lipid profile in pre- diabetes, non-diabetic and diabetic men and women. A cross-sectional study has been carried out in a total of 45 subjects for 20 subjects of pre-diabetes, 20 subjects of diabetic and 5 non-diabetic, south Indian rural 23 women and 22 men. Anthropometry was done for all the subjects with calibrated weighing machine, height scale etc. There is strong association between anthropometry and leptin resistance in both impaired and diabetic groups. In women both groups well correlated with total cholesterol and LDL. Increased serum Leptin levels/ leptin resistance was more evident in pre- diabetics when compared to non-diabetic and recent on set diabetes men and women.

Keywords: Diabetes, Cholesterol, Hdl, Ldl, Leptin.



This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

Introduction

Diabetes as well as pre-diabetes or impaired glucose tolerance increases the risk of cardiovascular disease by 2–3 times and increases by as much as 50% the risks of non-cardiovascular mortality associated with this condition[1]. This high risk is not completely explained by the traditional risk factors[2,3]. Pre-diabetes is also associated with cardiovascular diseases (CVD)[4-6], but it is unclear if it is an independent risk factor, because it commonly co-exists with other cardiovascular risk factors present in the metabolic syndrome. Obesity and associated factors play important role in pre-diabetes in the Indian population. Serum leptin levels increase with body fat mass, as leptin resistance and not leptin deficiency. Role of this leptin

resistance within India is not much studied in pre-diabetics. In human beings, serum leptin concentration is directly proportional to body fat mass, but it is leptin resistance and not leptin deficiency *per se* which is regarded as a pathogenic mechanism in human obesity. Leptin concentrations vary widely among individuals with similar fat mass, indicating other possible factors for its determination[7-10]. Leptin may be a marker of risk of CHD, at least in males, and contributes to the CHD risk profile in subjects with insulin resistance[11-14]

This study aim is to measure serum leptin levels in correlation with anthropometry and lipid profile in pre- diabetes, non-diabetic and diabetic men and women.



*Correspondence

Dr. Koppukonda Ravi Babu

Assistant Professor, Department of Biochemistry, Mallareddy Institute of Medical Sciences, Hyderabad, Telangana, India

E-mail: koppukonda@yahoo.com




Fig No.1: Effectors PYY3-36 GLP-1 Leptin (adipose)Insulin(pancreas)PYY3-36 GLP1 (gut)Satiety signals Ghrelin(stomach)HungersignalAdipositysignals(gut)Satiety signalsGhrelin (stomach) HungersignalMuscleAdiposeLiverHypothalamusSecond-orderneuronsArcuate neurons Organs “Eat less, metabolize more” “ Eat more, metabolize less” a-MSH NPY.




Fig No.2: A possible mechanism for cross talk between receptors for insulin and leptin. The insulin receptor has intrinsic Tyr kinase activity and the leptin receptor, when occupied by its ligand, is phosphorylated by a soluble Tyr kinase (JAK). One possible explanation for the observed interaction between leptin and insulin is that both may phosphorylate the same substrate—in the case shown here, insulin receptor substrate-2 (IRS-2). When phosphorylated, IRS-2 activates PI3K, which has downstream consequences that include inhibition of food intake. IRS-2 serves here as an integrator of the input from two receptors.

Materials and methods

A cross-sectional study has been carried out in a total of 45 subjects for 20 subjects of pre-diabetes , 20 subjects of diabetic and 5 non- diabetic, south Indian rural 23 women and 22 men. Anthropometry was done for all the subjects with calibrated weighing machine, height scale etc. Serum fasting leptin levels were measured by double sandwich ELISA method with Bio-rad fully automated ELISA reader. Lipid Profile was measured by Beck -man coulter fully automated bio-chemical analyser.



Fig No.3: ELISA READER

Waist Circumference to Height Measurements (feet and inches) to calculate ratios and risks
Source: janderson99 - Original Image




Fig NO4: Height measurements to calculate ratios and risk

HEALTH CARE 8/27/2015 4:14:29 PM
 Plate Name :
 Tech ID : Kit.Batch :
 Filter : 450 nm Plate Status : : MeanBlank = 0.071
 Regression : Linear

	1	2	3	4	5	6	7	8	9	10	11	12	
A	Std1 300 1.561	IM6 11 435.77 0.841	DM4 15 511.69 0.986	IF2 27 451.48 0.871	IF10 35 447.81 0.864	DF8 43 380.79 0.736	51 341. 0.660	14 59 308.53 0.598	22 67 490.22 0.345	30 75 387.07 0.748	37 83 357.23 0.032		
B	Std2 400 0.701	IM7 12 368.75 0.713	DM5 20 325.29 0.638	IF3 28 439.95 0.843	DF1 36 441.53 0.852	DF9 44 567.12 1.894	52 549.91 1.058	15 60 345.19 0.668	24 68 395.45 0.764	31 75 387.0 0.748	39 84 357.23 0.691		
C	Std3 200 0.407	IM8 10 444.67 0.858	DM6 21 368.22 0.712	IF4 29 442.05 0.853	DF2 37 381.31 0.737	DF10 45 449.38 0.867	53 454.62 0.877	8 61 417.44 0.806	16 69 381.84 0.738	24 77 1097.5 2.105	32 85 344.14 0.556		
D	Std4 100 0.219	IM1 6 307.0 0.743	IM9 14 370.17 0.848	DM7 22 438.43 0.917	IFS 30 475.55 0.914	DF3 38 421.63 0.672	NM1 46 347.28 0.694	9 54 337.85 0.654	17 52 340.47 0.653	25 70 405.32 0.784	33 86 323 -0.003	41 86 1.7 0.012	
E	Std5 50 0.116	IM2 7 320.58 0.621	IM10 15 338.38 0.808	DM8 23 133.65 0.284	IF6 31 351.99 0.601	DF4 39 281.31 0.546	47 402.78 0.778	2 55 421.11 0.813	10 63 380.27 0.735	18 71 350.42 0.576	26 89 1089.74 2.050	34 87 235.23 0.450	
F	0.000	IM3 8 404.35 0.761	DM1 15 354.81 0.686	DM9 24 387.07 0.748	IF7 32 1231.64 2.361	DF5 40 311.15 0.603	48 1017.49 1.952	3 56 446.72 0.860	11 54 -10.34 -0.011	19 72 306.5 0.766	27 88 424.26 0.819	35 88 346.33 0.670	
G	NM1 1 334.71 0.646	IM4 9 441.53 0.852	DM2 17 3291.26 0.565	DM10 25 344.55 0.687	IF8 33 342.57 0.563	DF6 41 365.51 0.707	49 443.1 0.655	4 57 438.39 0.846	12 65 429.49 0.828	20 73 459.33 0.886	28 81 15.48 0.944	36 89 1000.00 1.964	
14 Y	NM2 1 369.27 0.714	IM5 10 354.04 0.704	DM3 10 326.34 0.552	IF1 20 298.05 0.578	IF9 34 1008.59 1.935	DF7 42 383.41 0.741	5 90 906.48 1.740	6 58 406.45 0.785	21 66 347.8 0.673	29 74 351.42 0.533	37 82 247.8 0.462	45 90 275.02 0.334	

Fig NO.5 : calculation of linear regression

Plate Name : Health Care 8/28/2015 4:14:29 PM
 Tech ID : :
 Filter : 450 nm :
 Regression : Linear :
 Kit.Batch : :
 Plate Status : : MeanBlank = 0.071

	1	2	3	4	5	6	7	8	9	10	11	12
A	Std1 300 1.561	NF1 3 395.99 1.147	IM6 11 435.77 0.841	DM4 19 511.69 0.986	IF2 27 451.48 0.871	IF10 35 447.81 0.864	DF8 43 380.79 0.736	51 4 341. 0.660	14 59 308.53 0.598	72 67 490.22 0.345	30 75 387.07 0.748	37 83 12.18 0.032
B	Std2 400 0.781	NF2 4 323.19 0.628	IM7 12 368.75 0.713	DM5 20 325.29 0.638	IF3 28 439.95 0.843	DF1 36 441.53 0.852	DF9 44 567.12 0.833	52 2 549.51 1.058	15 60 343.19 0.668	23 68 393.43 0.704	31 75 387.0 0.748	39 84 337.23 0.691
C	Std3 200 0.407	NF3 5 444.67 0.858	IM8 10 487.08 0.553	DM6 21 368.22 0.712	IF4 29 442.05 0.853	DF2 37 381.31 0.737	DF10 45 449.38 0.867	53 8 454.62 0.877	16 61 417.44 0.906	24 69 381.84 0.738	32 77 1097.5 2.105	40 85 344.14 0.555
D	Std4 100 0.219	IM1 6 397.9 0.743	IM9 14 370.17 0.731	DM7 22 439.43 0.848	IF5 30 475.55 0.917	DF3 38 421.53 0.814	NM1 46 347.28 0.672	54 337.85 340.47 0.654	62 340.47 405.92 0.659	70 405.92 5.29 0.784	78 5.29 1.7 0.003	86 1.7 0.012
E	Std5 50 0.118	IM2 7 320.58 0.621	IM10 15 338.38 0.808	DM8 23 433.65 0.884	IF6 31 351.99 0.681	DF4 39 281.31 0.548	47 2 402.78 0.778	55 10 421.11 0.813	63 380.27 350.42 0.735	71 350.42 2.830 0.678	79 1089.74 2.830 0.450	87 235.23 0.450
F	0.890	IM3 8 404.35 0.781	DM1 16 354.61 0.686	DM9 24 387.07 0.748	IF7 32 423.64 2.361	DF5 40 311.15 0.603	1017.40 1.952	448.72 0.860	-10.34 -0.011	306.6 0.768	434.26 0.813	345.03 0.670
G	NM1 1 334.71 0.648	IM4 9 441.53 0.852	DM2 17 291.25 0.565	DM10 25 344.55 0.687	IF8 33 342.57 0.663	DF6 41 365.61 0.707	49 4 443.1 0.855	57 438.39 429.49 0.846	65 429.49 459.33 0.828	73 459.33 18.45 0.880	81 18.45 0.844	89 1000.00 1.000
H	NM2 2 369.27 0.714	IM5 10 364.04 0.704	DM3 10 326.34 0.652	IF1 25 298.05 0.578	IF9 24 1008.59 1.935	DF7 42 383.41 0.741	50 5 906.48 1.740	58 406.45 0.785	66 347.8 0.673	74 351.42 0.633	82 247.8 0.482	90 275.02 0.334

Fig NO.6: calculation of linear regression





Figure NO.7: Obesity caused by defective leptin production. Both of these mice, which are the same age, have defects in the *OB* gene. The mouse on the right was injected daily with purified leptin and weighs 35 g. The mouse on the left got no leptin and consequently ate more food and was less active; it weighs 67 g.

Results

Data analyses were carried out by using the Statistical Package (SPSS 23.0). Kolmogorov-Smirnov was performed to test continuous variables for normality. Independent Student's t-test to compare means between groups of normally distributed data. P values <0.05 were considered significant. Leptin values increased with increased BMI (r=0.59), WHR and HDL in both pre-diabetes and diabetes men and women (p value 0.000 to 0.009) and With increased total cholesterol and LDL , leptin values increased in both groups of women (p value 0.001 to 0.004). In diabetic men, impaired men and women leptin values showed strong association with triglycerides (p value 0.005 to 0.016).

Table No 1: BMI- Lipid Profile

GR	AGE	WHR	FBS	WHR	BMI	BODY MASS INDEX				LIPID PROFILE				LEPTI N
						BMI_ UW <18.5	BMI_ N 18.5-2 2.9	BMI_O W23-2 4.9	BMI_O B >24.9	TC	TG	LDL	HDL	
M(n=22)	46.72 ±10.58	0.91± 0.03	141.8(43.11)	0.54±0. 048	25.36 ±2.55	0			25.36± 2.55	188. 86±3 5.86	232.1 8±11 3.77	107.6 8±25. 28	39.5 9 +8.4 7	370.1 3±38. 48
N(n=2)	49.5 (10.5)	0.95± 0.05	90 (6)	0.55±0 .055	21.25 ±0.35	0	21.25± 0.35			189± 15	136± 33	125.5 ±11.5	36± 3	363.5 ±22.5
IGT=10	49.5 (11.9)	0.89± 0.03	111.4(5.72)	0.52± 0.054	25.9± 1.92	0			25.9±1. 92	195. 1±36 3	206.4 ±104. 96	102.3 ±30.1 6	39.2 ± 9.4	384.1 +40.4 8
DM=10	43.4 (8.28)	0.92± 0.02	182.6(39.6)	0.56± 0.04	25.65 ±3.04	0			25.65± 3.04	182. 6±39 .6	277.2 ±133. 08	109.5 ±21.2	40.7 ± 8.3	357.5 ±37
FEMALE n=23	50.08 (6.62)	0.85± 0.06	131.17(37.9 0)	0.57± 0.06	26.98 ±3.77	0			26.98± 3.77	194. 65±2 7.11	169.4 7±90. 57	118.5 6±19. 63	38.3 9±6. 18	504.6 +194. 4
N n=3	41 (2.66)	0.78± 0.03	89.33(6.22)	0.51± 0.02	21.7± 2.13	0	21.7±2 .13			164. 33±2 1.11	85.33 ±11.1 1	102.6 6±8.2 2	44± 10.6 6	467.6 ± 68.8
IGT= n=10	51.4 (5.28)	0.85± 0.06	107.8(5.36)	0.587 ±0.03 9	27.99 ±3.83	0			27.99± 3.83	184. 4±22 2	153.7 ±64.8 4	113.8 ±14.2 4	39.3 ±4.9 6	537± 228
DM n=10	51.5 (7.3)	0.86± 0.05	167.1(55.34)	0.62± 0.051	27.57 ±3.26	0			27.57± 3.26	214± 29.4	210.5 ± 61.44	128.1 ± 26.14	35.8 ± 7.04	483.4 ± 201.6









Table No.2: Case Processing Summary

	Df	Cases					
		Valid		Missing		Total	
		N	Percent	N	Percent	N	Percent
Leptin	DF	10	100.0%	0	0.0%	10	100.0%
LDL		10	100.0%	0	0.0%	10	100.0%

Table No 3: Tests of Normality

	DF	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
		Leptin	DF	.363	10	.001	.647
LDL		.201	10	.200*	.939	10	.542

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction




Figure No 8: Histograms of HDL & LDL

Discussion

South Asians, including Indian, Pakistanis, Sri Lankans and Bangladeshis serum leptin levels in a group of type 2diabetics residing in district Rawalpindi, Pakistan. The main findings of study are: type 2 diabetes is associated with marked reduction in serum leptin level in both men and women; serum leptin level is strongly associated with BMI in obese person- diabetics or non diabetics; in

multiple regression analysis only BMI predicted serum leptin level. Serum leptin is found high in diabetics taking oral hypoglycemic, mean 37.8±19.1 ng/ml while it is low in diabetics taking insulin injections 29.3±24.2 ng/ml. This may be due to decreased insulin secretion in patients taking exogenous insulin. In some studies treatment of diabetes with sulfonylureas has been reported to increase serum leptin levels but not in other studies. In these studies, the effect

of sulfonylureas was mediated through changes in body weight or improved insulin secretion⁴ We observed a clear difference between BMI of both the groups. It is high in patients (n=30) receiving oral hypoglycaemics (mostly sulfonylureas) and low in patients (n=20) receiving insulin which is in accordance with above mentioned studies. This may be due to decreased insulin secretion in patients taking exogenous insulin. In some studies treatment of diabetes with sulfonylureas has been reported to increase serum leptin levels⁴ but not in other studies. In these studies, the effect of sulfonylureas was mediated through changes in bodyweight or improved insulin secretion. We observed a clear difference between BMI of both the groups. It is high in patients (n=30) receiving oral hypoglycaemics (mostly sulfonylureas) and low in patients (n=20) receiving insulin which is in accordance with above mentioned studies

An association between polymorphisms in the LEPR gene with glucose and insulin metabolism in overweight and obese women with IGT. This suggests that these genetic polymorphisms could affect the peripheral function of the LEPR in the regulation of insulin secretion and especially on insulin action. Fasting serum leptin levels ranged from 3.3–16.8 ng/mL (mean, 7.6 ng/dL). In contrast to glucose disposal, fasting serum leptin levels were highly correlated with sc, but not visceral, adipose tissue. As might be expected, serum leptin was not correlated with glucose disposal or plasma lipids. The correlation of leptin levels with BMI ($r=0.81$, $P=0.0001$) reflects the high correlation of BMI. Data were presented according to gender, since it is already an established fact that leptin levels are significantly higher in women than in men. There are several possible explanations for the difference. One is that females have more adipose tissue than males, but a growing literature indicates that estrogen, especially at higher levels, will stimulate the production of leptin, whereas androgens will suppress the levels of leptin.

Conclusion

There is strong association between anthropometry and leptin resistance in both impaired and diabetic groups. In women both groups well correlated with total cholesterol and LDL. Increased serum Leptin levels/ leptin resistance was more evident in pre-diabetics when compared to non-diabetic and recent onset diabetes men and women.

References

1. Thomas RL, Dunstan FD, Luzio SD, Chowdhury SR, North RV, Hale SL, et al. Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service. *Br J Ophthalmol*. 2015;99(1):64-8.
2. Song SJ, Han K, Choi KS, Ko SH, Rhee EJ, Park CY, et al. Trends in diabetic retinopathy and related medical practices among type 2 diabetes patients: Results from the National Insurance Service Survey 2006-2013. *J Diabetes Investig*. 2018;9(1):173-8. doi: 10.1111/jdi.12655 pmid: 28294558
3. Ting DS, Cheung GC, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. *Clin Exp Ophthalmol*. 2016;44(4):260-77. doi: 10.1111/ceo.12696 pmid: 26716602
4. Javadi MA, Katibeh M, Rafati N, Dehghan MH, Zayeri F, Yaseri M, et al. Prevalence of diabetic retinopathy in Tehran province: a population-based study. *BMC Ophthalmol*. 2009;9:12. doi: 10.1186/1471-2415-9-12 pmid: 19835608
5. Kyari F, Tafida A, Sivasubramaniam S, Murthy GV, Peto T, Gilbert CE, et al. Prevalence and risk factors for diabetes and diabetic retinopathy: results from the Nigeria national blindness and visual impairment survey. *BMC Public Health*. 2014;14:1299.
6. Sabanayagam C, Yip W, Ting DS, Tan G, Wong TY. Ten Emerging Trends in the Epidemiology of Diabetic Retinopathy. *Ophthalmic Epidemiol*. 2016;23(4):209-22. doi: 10.1080/09286586.2016.1193618 pmid: 27355693
7. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. *Diabetes Care*. 2012;35(3):556-64. doi: 10.2337/dc11-1909 pmid: 22301125
8. Tomic M, Ljubic S, Kastelan S, Gverovic Antunica A, Jazbec A, Poljicanin T. Inflammation, haemostatic disturbance, and obesity: possible link to pathogenesis of diabetic retinopathy in type 2 diabetes. *Mediators Inflamm*. 2013;2013:818671. doi: 10.1155/2013/818671 pmid: 24363502
9. Anan F, Masaki T, Ito Y, Eto T, Umeno Y, Eshima N, et al. Diabetic retinopathy is associated with visceral fat accumulation in Japanese type 2 diabetes mellitus patients. *Metabolism*. 2010;59(3):314-9. doi: 10.1016/j.metabol.2009.06.001 pmid: 20004426
10. Rooney D, Lye WK, Tan G, Lamoureux EL, Ikram MK, Cheng CY, et al. Body mass index and retinopathy in Asian populations with diabetes mellitus. *Acta Diabetol*. 2015;52(1):73-80. doi: 10.1007/s00592-014-0602-2 pmid: 24880522.
11. Thivel D, O'Malley G, Pereira B, Duche P, Aucouturier J. Comparison of total body and abdominal adiposity indexes to dual x-ray absorptiometry scan in obese adolescents. *Am J Hum Biol*. 2015;27(3):334-8. doi: 10.1002/ajhb.22643 pmid: 25327573
12. Borer KT. Counterregulation of insulin by leptin as key component of autonomic regulation of body weight. *World J Diabetes*. 2014;5(5):606-29. doi: 10.4239/wjd.v5.i5.606 pmid: 25317239
13. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. *N Engl J Med*. 1996;334(5):292-5. doi: 10.1056/NEJM199602013340503 pmid: 8532024
14. Pradeepa R, Surendar J, Indulekha K, Chella S, Anjana RM, Mohan V. Association of serum adiponectin with diabetic microvascular complications among south Indian type 2 diabetic subjects - (CURES-133). *Clin Biochem*. 2015;48(1-2):33-8.

Conflict of Interest: Nil Source of support: Nil